Mariana Do Carmo
About
Research
Publications
2023
Oncogenic context shapes the fitness landscape of tumor suppression
Blair L, Juan J, Sebastian L, Tran V, Nie W, Wall G, Gerceker M, Lai I, Apilado E, Grenot G, Amar D, Foggetti G, Do Carmo M, Ugur Z, Deng D, Chenchik A, Paz Zafra M, Dow L, Politi K, MacQuitty J, Petrov D, Winslow M, Rosen M, Winters I. Oncogenic context shapes the fitness landscape of tumor suppression. Nature Communications 2023, 14: 6422. PMID: 37828026, PMCID: PMC10570323, DOI: 10.1038/s41467-023-42156-y.Peer-Reviewed Original Research
2022
Systematic identification of biomarker-driven drug combinations to overcome resistance
Rees M, Brenan L, do Carmo M, Duggan P, Bajrami B, Arciprete M, Boghossian A, Vaimberg E, Ferrara S, Lewis T, Rosenberg D, Sangpo T, Roth J, Kaushik V, Piccioni F, Doench J, Root D, Johannessen C. Systematic identification of biomarker-driven drug combinations to overcome resistance. Nature Chemical Biology 2022, 18: 615-624. PMID: 35332332, DOI: 10.1038/s41589-022-00996-7.Peer-Reviewed Original Research
2020
Rhabdoid Tumors Are Sensitive to the Protein-Translation Inhibitor Homoharringtonine
Howard T, Oberlick E, Rees M, Arnoff T, Pham M, Brenan L, DoCarmo M, Hong A, Kugener G, Chou H, Drosos Y, Mathias K, Ramos P, Seashore-Ludlow B, Giacomelli A, Wang X, Freeman B, Blankenship K, Hoffmann L, Tiv H, Gokhale P, Johannessen C, Stewart E, Schreiber S, Hahn W, Roberts C. Rhabdoid Tumors Are Sensitive to the Protein-Translation Inhibitor Homoharringtonine. Clinical Cancer Research 2020, 26: 4995-5006. PMID: 32631955, PMCID: PMC7501142, DOI: 10.1158/1078-0432.ccr-19-2717.Peer-Reviewed Original ResearchAcquired Resistance to HER2-Targeted Therapies Creates Vulnerability to ATP Synthase Inhibition
Gale M, Li Y, Cao J, Liu ZZ, Holmbeck MA, Zhang M, Lang SM, Wu L, Do Carmo M, Gupta S, Aoshima K, DiGiovanna MP, Stern DF, Rimm DL, Shadel GS, Chen X, Yan Q. Acquired Resistance to HER2-Targeted Therapies Creates Vulnerability to ATP Synthase Inhibition. Cancer Research 2020, 80: 524-535. PMID: 31690671, PMCID: PMC7002225, DOI: 10.1158/0008-5472.can-18-3985.Peer-Reviewed Original ResearchAnimalsAntineoplastic Combined Chemotherapy ProtocolsApoptosisBreast NeoplasmsCell ProliferationDrug Resistance, NeoplasmEnzyme InhibitorsFemaleHumansMiceMice, Inbred NODMice, SCIDMitochondrial Proton-Translocating ATPasesOligomycinsReceptor, ErbB-2TrastuzumabTumor Cells, CulturedXenograft Model Antitumor AssaysDefining the landscape of ATP-competitive inhibitor resistance residues in protein kinases
Persky NS, Hernandez D, Do Carmo M, Brenan L, Cohen O, Kitajima S, Nayar U, Walker A, Pantel S, Lee Y, Cordova J, Sathappa M, Zhu C, Hayes TK, Ram P, Pancholi P, Mikkelsen TS, Barbie DA, Yang X, Haq R, Piccioni F, Root DE, Johannessen CM. Defining the landscape of ATP-competitive inhibitor resistance residues in protein kinases. Nature Structural & Molecular Biology 2020, 27: 92-104. PMID: 31925410, DOI: 10.1038/s41594-019-0358-z.Peer-Reviewed Original Research
News
News
- April 08, 2026
Lung Cancer: How Tumors Develop, Resist Treatment, and What Comes Next
- November 04, 2022
Albertus Magnus Cancer Research Student Science Day